Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

1. WO2012001156 - FORMES PHARMACEUTIQUES POSOLOGIQUES ORALES COMPRENANT DE L'ÉTÉXILATE DE DABIGATRAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES

Numéro de publication WO/2012/001156
Date de publication 05.01.2012
N° de la demande internationale PCT/EP2011/061140
Date du dépôt international 01.07.2011
CIB
A61K 9/50 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
9Préparations médicinales caractérisées par un aspect particulier
48Préparations en capsules, p.ex. de gélatine, de chocolat
50Microcapsules
A61K 31/4439 2006.01
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
31Préparations médicinales contenant des ingrédients actifs organiques 
33Composés hétérocycliques
395ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
435ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
44Pyridines non condensées; Leurs dérivés hydrogénés
4427contenant d'autres systèmes hétérocycliques
4439contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
CPC
A61K 31/4439
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
4439containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 9/1617
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1605Excipients; Inactive ingredients
1617Organic compounds, e.g. phospholipids, fats
A61K 9/1623
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1605Excipients; Inactive ingredients
1617Organic compounds, e.g. phospholipids, fats
1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
A61K 9/1652
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1605Excipients; Inactive ingredients
1629Organic macromolecular compounds
1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
A61K 9/167
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
167with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
A61K 9/1682
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
1682Processes
Déposants
  • KRKA, TOVARNA ZDRAVIL, D.D., NOVO MESTO [SI/SI]; Smarjeska cesta 6 8501 Novo mesto, SI (AllExceptUS)
  • KROSELJ, Vesna [SI/SI]; SI (UsOnly)
Inventeurs
  • KROSELJ, Vesna; SI
Mandataires
  • UEXKÜLL & STOLBERG; Beselerstr. 4 22607 Hamburg, DE
Données relatives à la priorité
P-20100019601.07.2010SI
P-20100020912.07.2010SI
Langue de publication anglais (EN)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) PHARMACEUTICAL ORAL DOSAGE FORMS COMPRISING DABIGATRAN ETEXILATE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
(FR) FORMES PHARMACEUTIQUES POSOLOGIQUES ORALES COMPRENANT DE L'ÉTÉXILATE DE DABIGATRAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
Abrégé
(EN)
The invention relates to pharmaceutical oral dosage forms of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate (dabigatran etexilate) and the pharmacologically acceptable salts thereof, in particular dabigatran etexilate methanesulfonate.
(FR)
L'invention porte sur des formes pharmaceutiques posologiques orales du principe actif du 3-[(2-{[4-(hexyloxycarbonylaminoiminométhyl)phénylamino]méthyl}-1-méthyl-1H-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionate d'éthyle (étéxilate de dabigatran) et des sels pharmacologiquement acceptables de celui-ci, en particulier du méthanesulfonate d'étéxilate de dabigatran.
Également publié en tant que
Dernières données bibliographiques dont dispose le Bureau international